GlaxoSmithKline, Vir Covid-19 Treatment Gets EU Approval
December 17 2021 - 8:34AM
Dow Jones News
By Jaime Llinares Taboada
GlaxoSmithKline PLC said Friday that the European Commission has
approved its sotrovimab antibody for the early treatment of
Covid-19.
The pharmaceutical company and Vir Biotechnology Inc. said the
EC, the executive branch of the European Union, has granted
marketing authorization.
The product is now approved for the treatment of adults and
adolescents at risk of progressing to severe Covid-19.
In July, GSK and Vir reached a deal with the EU to supply up to
220,000 doses of sotrovimab.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
December 17, 2021 08:19 ET (13:19 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024
